Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

Liquidia (NASDAQ:LQDA) will present four posters at the PHA 2026 International PH Conference and Scientific Sessions in Dallas, June 11-14, 2026.

Rhea-AI Summary

Liquidia (NASDAQ:LQDA) will present four posters at the PHA 2026 International PH Conference and Scientific Sessions in Dallas, June 11-14, 2026.

Posters cover ASCENT study data on YUTREPIA in PH-ILD, patient-reported cough, caregiver mental health, pharmacist roles, and an encore of safety and exploratory efficacy data.

Argus Jun 11 session

+9.77% close to close Open Argus

Details

News Market Reaction – LQDA

On Jun 11, the day this news came out, LQDA closed 9.77% above the previous close.

Data tracked by StockTitan Argus for the Jun 11 session.

Key Figures

ASCENT treatment duration: 24 weeks Number of posters: 4 posters Conference dates: June 11–14, 2026 +3 more

ASCENT treatment duration

24 weeks

Patient-reported cough outcomes in PH-ILD over 24 weeks

Number of posters

4 posters

Total posters presented at PHA 2026 International PH Conference

Conference dates

June 11–14, 2026

PHA 2026 International PH Conference and Scientific Sessions in Dallas

Poster session time

4–5 p.m. CDT

Scheduled time for all poster presentations on June 11

Poster 1014

Poster #1014

Self-reported cough outcomes with YUTREPIA in ASCENT trial

Poster 1060

Poster #1060

Encore safety and exploratory efficacy data to Week 24 in PH-ILD

Historical Context

5 past events · Latest: Jun 08

5 events

1. Jun 08

   Index inclusion

   24h Move

   +4.4%

   Announced upcoming addition to the S&P SmallCap 600 Index.

2. May 27

   Conference appearance

   24h Move

   +3.2%

   Planned Jefferies conference fireside chat on company business.

3. May 11

   Earnings results

   24h Move

   +25.6%

   Reported strong Q1 2026 results driven by YUTREPIA sales.

4. May 06

   Investor conferences

   24h Move

   +5.0%

   Planned participation in two May 2026 investor conferences.

5. May 04

   Earnings date set

   24h Move

   +0.9%

   Scheduled Q1 2026 results release and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pulmonary hypertension, interstitial lung disease, treprostinil, inhalation powder

4 terms

pulmonary hypertension medical

"caregivers of patients with pulmonary hypertension"

Pulmonary hypertension is a condition where the blood vessels in the lungs become narrowed or stiff, forcing the right side of the heart to work much harder to push blood through—imagine a pump trying to push water through narrower pipes. For investors, it matters because the condition drives demand for diagnostic tests, ongoing treatments, and new drugs; changes in clinical trial results, approvals, or treatment guidelines can meaningfully affect the commercial prospects and costs for companies focused on this disease.

interstitial lung disease medical

"pulmonary hypertension associated with interstitial lung disease (PH-ILD)"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

treprostinil medical

"YUTREPIA® (treprostinil) inhalation powder"

Treprostinil is a prescription drug that widens and relaxes the small blood vessels in the lungs to lower high blood pressure there and help people breathe and move more easily; it comes in several forms such as injection, infusion, inhalation or tablets. For investors it matters because approval status, patent protection, manufacturing complexity, competition from other treatments, and ongoing clinical trials directly affect a company’s sales potential, regulatory risk, and long-term revenue—think of it as a product line whose market success depends on safety, access, and differentiation.

inhalation powder medical

"YUTREPIA® (treprostinil) inhalation powder"

A dose of medication manufactured as a dry powder that is inhaled into the lungs using a handheld device rather than swallowed or injected. Think of it like a measured spoonful of powdered spice delivered through a shaker built to fit the airway; the powder must reach specific lung regions to work. Investors care because the drug's safety, ease of use, manufacturing costs, device patents and regulatory pathway all affect commercial success and market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that the company will present four posters at the PHA 2026 International PH Conference and Scientific Sessions taking place June 11-14 in Dallas.

Liquidia will present data from Cohort A of its ASCENT study of YUTREPIA^® (treprostinil) inhalation powder, including patient-reported cough outcomes in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) over 24 weeks of treatment. The company will also present new data and analyses examining the role of pharmacists within PH care teams and the mental health burden experienced by caregivers of patients with PH. In addition, Liquidia will present an encore of previously reported safety and exploratory efficacy data from the ASCENT study.

Dr. Rajeev Saggar, Liquidia Chief Medical Officer, said: “We are proud to share our research with the patients and caregivers at the center of the pulmonary hypertension community. From listening to patients describe their own experience with treatment to understanding the burden carried by caregivers and the role of the care teams who support them, this work reflects our commitment to the people living with this condition every day.”

All posters will be presented from 4 to 5 p.m. CDT Thursday, June 11, in the exhibition hall. Upon presentation, each publicly presented poster will be available on the publications page of Liquidia’s website at https://liquidia.com/publications.

New Poster Presentations

Poster #1014
Hearing from Patients: Self-Reported Cough Outcomes During Treatment with YUTREPIA^® (treprostinil) in the ASCENT Trial

Poster #1055
The Invisible Burden: Mental Health Challenges Facing Caregivers of Patients with Pulmonary Hypertension

Poster #1072
The PHriendly Neighborhood Pharmacist: Mapping the Pharmacist’s Role in Pulmonary Hypertension Care Teams

Encore Presentation
Poster #1060
A Continued ASCENT to Week 24: Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients

About YUTREPIA^® (treprostinil) Inhalation Powder

YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT^® technology. PRINT enabled the development of YUTREPIA^® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Investor Contact:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com

Media Contact:
media@liquidia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Liquidia (NASDAQ:LQDA) presenting at the PHA 2026 International PH Conference?

Liquidia is presenting four scientific posters at the PHA 2026 International PH Conference. According to Liquidia, topics include ASCENT study data on YUTREPIA in PH-ILD, cough outcomes, caregiver mental health, pharmacist roles, and an encore of safety and exploratory efficacy results.

When and where will Liquidia present its posters at PHA 2026?

Liquidia’s posters will be presented on Thursday, June 11, 2026, from 4–5 p.m. CDT. According to Liquidia, the sessions will take place in the exhibition hall at the PHA 2026 International PH Conference and Scientific Sessions in Dallas, Texas.

What ASCENT study data on YUTREPIA will Liquidia share at PHA 2026?

Liquidia will share Cohort A data from its ASCENT study of YUTREPIA inhalation powder in PH-ILD. According to Liquidia, this includes patient-reported cough outcomes over 24 weeks of treatment and an encore poster with safety and exploratory efficacy data through Week 24.

How can investors access Liquidia’s PHA 2026 poster presentations on YUTREPIA and PH-ILD?

Investors can view the posters online after they are presented at PHA 2026. According to Liquidia, each publicly presented poster will be available on the publications page of the company’s website at the URL https://liquidia.com/publications.

What caregiver mental health data is Liquidia highlighting at PHA 2026 for LQDA shareholders?

Liquidia is presenting a poster on mental health challenges facing caregivers of patients with pulmonary hypertension. According to Liquidia, this new analysis focuses on the “invisible burden” carried by caregivers, adding context on patient-support needs beyond core clinical outcomes.

What role of pharmacists in pulmonary hypertension care is Liquidia presenting at PHA 2026?

Liquidia is presenting a poster mapping the pharmacist’s role in pulmonary hypertension care teams. According to Liquidia, this work examines how pharmacists contribute within PH care teams, complementing clinical data from the ASCENT study and other insights shared at the conference.